Marie Maerevoet

Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial

Umberto Vitolo, Juan Miguel Bergua Burgués, Johannes Duell, Michal Kwiatek et autres

it, es, de, gb, cz, pl, be, fr, at, jp, kr, us (code pays fourni par la source)

Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3

Umberto Vitolo, Johannes Duell, Juan Miguel Bergua Burgués, Wojciech Jurczak et autres

Abstract Introduction: A proportion of newly diagnosed (1L) patients (pts) with LBCL are ineligible for standard curative chemotherapy with full-dose R-CHOP due to age or comorbidities. Alternative regimens (eg, R-mini-CHOP) and other investigational single-agent bispecifics have shown limited efficacy in the 1L …

it, de, es, hu, us, be, cz, kr, at, fr, jp (code pays fourni par la source)

Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study

Olivier Tournilhac, Solene Lecolant, Maya Hacini, Kamel Laribi et autres

ABSTRACT: We aim to evaluate the efficacy of brentuximab vedotin (BV) combined with gemcitabine (GBV) followed by BV maintenance in relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL). Patients with at least 5% CD30+ cells by immunohistochemistry received 4 GBV induction (28 …

fr, be, ch (code pays fourni par la source)

Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelines

Loïc Renaud, Marie Donzel, Justine Decroocq, Pierre Decazes et autres

Primary mediastinal B-cell lymphoma (PMBCL) is a distinct subtype of large B-cell lymphoma with unique clinical, histopathological, and molecular characteristics. Despite its aggressive nature, PMBCL has a high cure rate when managed appropriately. Advances in the understanding of PMBCL biological characteristics, coupled …

fr, be, re (code pays fourni par la source)

Combination of Brentuximab Vedotin and Pembrolizumab as Salvage Treatment Before Autologous Stem Cell Transplantation and Maintenance in Patients with Relapsed/Refractory Hodgkin Lymphoma

Hanne Massa, Fulvio Massaro, Marie Maerevoet

Background: In relapsed or refractory classical Hodgkin lymphoma, achieving complete remission on 18FDG PET-CT before autologous stem cell transplantation improves progression-free survival. However, the optimal salvage therapy to achieve this remains undefined. Brentuximab vedotin combined with PD1 inhibitors has shown promise, though …

be (code pays fourni par la source)

Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines

Cédric Rossi, Guillaume Manson, Amira Marouf, Aurélie Cabannes-Lamy et autres

Classic Hodgkin lymphoma (HL) is a distinct entity among hematological malignancies of B-cell origin. It is characterized by its unique histopathological features and generally favorable prognosis. Over the years, advancements in understanding its pathogenesis, coupled with refined diagnostic and evaluation modalities, as …

fr, be, ch, us (code pays fourni par la source)

Phase IB Study of Oral Selinexor in Combination with Rituximab and Platinum Chemotherapy in Patients with Relapsed/Refractory B-Cell Lymphoma—Final Analysis

Marie Maerevoet, Olivier Casasnovas, Guillaume Cartron, Franck Morschhauser et autres

PURPOSE: Selinexor is an oral selective inhibitor of exportine-1 (XPO1) with efficacy as a single agent in heavily pretreated diffuse large B-cell lymphoma (DLBCL). We conducted a study investigating the combination of selinexor with rituximab and platinum-based chemotherapy in B-cell lymphoma. PATIENTS …

be, fr (code pays fourni par la source)

Supplementary Data Tables from The Light Chain IgLV3-21 Defines a New Poor Prognostic Subgroup in Chronic Lymphocytic Leukemia: Results of a Multicenter Study

Basile Stamatopoulos, Tom Smith, Emerence Crompot, Karlien Pieters et autres

Supplementary Data Table S1: general characterisctic of the different cohorts of patients Supplementary Data Table S2: characterisctic of Population A Supplementary Data Table S3: characterisctic of Population B Supplementary Data Table S4: characterisctic of Population C Supplementary Data Table S5: characterisctic of …

Supplementary Data from The Light Chain IgLV3-21 Defines a New Poor Prognostic Subgroup in Chronic Lymphocytic Leukemia: Results of a Multicenter Study

Basile Stamatopoulos, Tom Smith, Emerence Crompot, Karlien Pieters et autres

Supplementary Data Figure S1. Determination of IgLV3-21 positivity by real-time PCR. Supplementary Data Figure S2: CLL-OS analysis including only CLL-related deaths. Supplementary Data Figure S3. Validation of the poor prognosis associated with IgLV3-21 usage in population C. Supplementary Data Figure S4. Validation …

Supplementary methods from Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies

Philippe Aftimos, Christian Rolfo, Sylvie Rottey, Fritz Offner et autres

More details about inclusion and exclusion criteria

Supplementary Data from The Light Chain IgLV3-21 Defines a New Poor Prognostic Subgroup in Chronic Lymphocytic Leukemia: Results of a Multicenter Study

Basile Stamatopoulos, Tom Smith, Emerence Crompot, Karlien Pieters et autres

Supplementary Data Figure S1. Determination of IgLV3-21 positivity by real-time PCR. Supplementary Data Figure S2: CLL-OS analysis including only CLL-related deaths. Supplementary Data Figure S3. Validation of the poor prognosis associated with IgLV3-21 usage in population C. Supplementary Data Figure S4. Validation …

Supplementary Data Tables from The Light Chain IgLV3-21 Defines a New Poor Prognostic Subgroup in Chronic Lymphocytic Leukemia: Results of a Multicenter Study

Basile Stamatopoulos, Tom Smith, Emerence Crompot, Karlien Pieters et autres

Supplementary Data Table S1: general characterisctic of the different cohorts of patients Supplementary Data Table S2: characterisctic of Population A Supplementary Data Table S3: characterisctic of Population B Supplementary Data Table S4: characterisctic of Population C Supplementary Data Table S5: characterisctic of …